The prior year Say on Pay vote received approximately 95% support, well above the 70% threshold that would require a negative response, and the compensation structure is sound: the CEO's total pay of approximately $11.9 million consists primarily of variable, at-risk components (stock options, restricted stock units, and a performance-based cash bonus), with base salary representing only about 7% of total compensation, well below the 40% fixed-pay ceiling. The annual cash bonus was capped at 120% of base salary and was earned based on rigorous, pre-disclosed corporate milestones including FDA approval of a new drug, hitting clinical enrollment targets, and commercial launch readiness goals — not easily manipulated short-term metrics. The company also has a formal clawback policy compliant with SEC and Nasdaq rules, stock ownership guidelines, and a double-trigger requirement for equity acceleration on a change of control, all of which represent best-practice governance features.

Ernst & Young has served as Cytokinetics' auditor since 2018 (approximately 8 years), well below the 25-year tenure threshold; non-audit fees for 2025 were zero, meaning 100% of fees were core audit fees and the non-audit ratio trigger does not apply; no material restatements are disclosed; and as a Big 4 firm auditing an $8.2 billion market-cap company, EY is clearly adequate for the company's size and complexity.